The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 220.00
Ask: 230.00
Change: 10.00 (4.65%)
Spread: 10.00 (4.545%)
Open: 215.00
High: 234.00
Low: 225.00
Prev. Close: 215.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron Provides Update at R&D Day

14 Jun 2016 07:00

RNS Number : 0477B
Faron Pharmaceuticals Oy
14 June 2016
 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

Faron Provides Update at R&D Day

TURKU - FINLAND 14 June 2016 - Faron Pharmaceuticals Ltd (LON: FARN), the clinical stage biopharmaceutical company, today presents an update on the Company's pipeline activities around Traumakine® and its novel cancer immunotherapy drug candidate Clevegen® at its R&D Day in London. On 26 May 2016 the Board of Directors announced that the development strategy for Clevegen has been expanded to open up new application opportunities in conditions where removal of suppression of local or systemic immunity is desirable. The Company has introduced two additional technology platforms related to Tumour Immunity Enabling Technology, or TIET to cover new development areas, chronic infections and inefficient vaccination.

The following updates are being presented at the R&D Day:

 

Clevegen:

An introduction of Chronic Infection Removal Therapy, CIRT, which would allow combat against bacteria, when they use M2 macrophages to hide host immune systemAn introduction of Vaccination Response Enhancement Technology, VRET to use Clevegen as an adjuvant in vaccination protocolsA potential key target group for TIET program, hepatocellular carcinoma (HCC) patients

 

Traumakine:

Faron is currently preparing plans for US safety trial as requested by FDAConfirmation that Faron plans to file Traumakine CTA in H2 2016 to the Finnish Medicines Agency (FIMEA) for clinical trial INFORAA on patients suffering from Rupture of Abdominal Aorta Aneurysm and operated surgically.

 

The updated Faron pipeline as of 14 June, 2016 can be found on the Company website: http://www.faronpharmaceuticals.com/pipeline

 

Dr. Markku Jalkanen, CEO of Faron, said: "We have clear plans to advance our exciting pipeline over the next two to three years and maintain focus on our most advanced projects Traumakine and Clevegen, which represent tremendous expansion potential into new indications and territories. Our Board fully recognise the potential of Clevegen towards several non-tumoural indications. Our scientific collaborators are already exploring these new CIRT and VRET technologies in order to provide pre-clinical data for our clinical plans. As stated on our TIET RNS on 26 May 2016, Faron plan to intensify commercial efforts around these three exciting technologies and make them available for interested licensing partners while at the same time focusing on our own development as well."

 

"Tumour Immunity Enabling Technology", or TIET, can be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. The Directors also believe that Clevegen's ability to convert M2 macrophages to M1 macrophages could provide additional applications to control immune suppression causing inadequate immune response. These are related to many chronic infections and inefficient vaccination due to low adjuvant effect. Faron will now introduce two additional technology platforms to cover these exciting development areas and starts to promote their development and use worldwide.

Presentations are available for viewing on Faron's Company website: http://www.faronpharmaceuticals.com/investor-relations/events

 

For more information, please contact:

 

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone +358 (50) 577 4807E-mail: katja.wallenlind@faronpharmaceuticals.com

 

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

 

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: +44 207 148 7900

 

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

 

Whitman Howard Limited, Nominated Broker

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

 

 

About Faron Pharmaceuticals Ltd.

 

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach called TIET (Tumour Immunity Enabling Technology). Faron Pharmaceuticals Ltd. is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

 

About Tumor Immunity Enabling Technology (TIET) 

 

The TIET technology is built around the humanised anti-Clever-1 antibody FP-1305, which binds to a specific Clever-1 proprietary epitope. Clevegen® binding to this epitope activates conversion of type 2 tumour associated macrophages to type 1 macrophages, resulting in the transformation of the tumour environment from immune suppression to immune activation. As the TIET technology is based on a humanised antibody, the Faron Directors believe it can be combined with a number of other immune therapies without a significant risk of increased adverse events. The TIET technology could provide a significant boost for the efficacy of other immune checkpoint molecules, as its target is unique and represents a completely separate control of immunity.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGUBAQUPQGCW
Date   Source Headline
19th Apr 20177:00 amRNSProposed Board Changes
18th Apr 20174:17 pmRNSPurchase of Shares
18th Apr 20177:00 amRNSCollaboration with Birmingham University
13th Apr 20171:43 pmRNSPurchase of Shares
4th Apr 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSFinal Results 2016
27th Mar 20179:23 amRNSHolding(s) in Company
21st Mar 201711:05 amRNSSecond Price Monitoring Extn
21st Mar 201711:00 amRNSPrice Monitoring Extension
7th Mar 201710:54 amRNSHolding(s) in Company
7th Mar 20177:00 amRNSNotice of Full Year Results
3rd Mar 201711:02 amRNSHolding(s) in Company
1st Mar 20172:05 pmRNSSecond Price Monitoring Extn
1st Mar 20172:00 pmRNSPrice Monitoring Extension
1st Mar 201711:35 amRNSResult of Placing & Subscription & Issue of Equity
28th Feb 20177:00 amRNSProposed Placing and Subscription
20th Feb 20177:00 amRNSFirst Patient Recruited in Phase II RAAA Study
9th Feb 20177:00 amRNSFaron update for 2017
9th Dec 20161:05 pmRNSNotification of Major Interest in Shares
9th Dec 20161:00 pmRNSNotification of Major Interest in Shares
5th Dec 20167:00 amRNSPDMR Shareholding
21st Nov 20167:00 amRNSGrant of options
31st Oct 20167:00 amRNSNew Application Accepted by Finnish Patent Office
24th Oct 20167:00 amRNSFirst patient recruited in Japanese Ph III trial
7th Oct 20161:41 pmRNSNotification of Major Interest in Shares
6th Oct 201610:00 amRNSNotification of Major Interest in Shares
5th Oct 20165:10 pmRNSNotification of Major Interest in Shares
26th Sep 20163:59 pmRNSDirector Dealing
21st Sep 201611:27 amRNSRaises £8.0 M through a Placing and Subscription
20th Sep 20167:00 amRNSProposed Placing & Subscription to raise £8M
5th Sep 20167:00 amRNSInterim Results for six months ended 30 June 2016
10th Aug 20167:00 amRNSFaron Pharmaceuticals Notice of Interim Results
25th Jul 20167:00 amRNSFaron enters agreement with Abzena for Clevegen
22nd Jun 201612:00 pmRNSFaron to Present at Proactive Investors Forum
14th Jun 20167:00 amRNSFaron Provides Update at R&D Day
13th Jun 20167:00 amRNSFaron Licenses Traumakine Rights to Pharmbio Korea
26th May 201610:53 amRNSFaron Result of Annual General Meeting
26th May 20167:00 amRNSFaron Expands R&D Strategy for Clevegen
13th May 20167:00 amRNSFaron Pharmaceuticals Ltd to host an R&D Day
4th May 20167:00 amRNSNotice of AGM
3rd May 20167:00 amRNSFaron Appoints New Medical Director
22nd Apr 20167:00 amRNSFaron Appoints Panmure Gordon as Joint Broker
19th Apr 20167:00 amRNSFaron Files Two New Patents to Protect Clevegen
10th Mar 20167:00 amRNSAnnual Results for the year ended 31 December 2015
1st Mar 20167:00 amRNSFaron files patent application for Traumakine
10th Feb 20167:00 amRNSNotice of Preliminary Results
7th Jan 20167:00 amRNSTop-line results from Japanese study of Traumakine
29th Dec 20157:00 amRNSFirst Patient recruited in Phase III ARDS Study
21st Dec 20157:00 amRNSFaron Awarded ?1.5 million Tekes Funding
30th Nov 20157:00 amRNSKey Publication in Journal of Immunology

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.